What happened
Yungjin Pharm filed provisional (unaudited) separate results for Q2 2026: revenue of US$43.3M (−1.5% year on year), an operating loss of US$1.05M (from a profit a year earlier) and a net loss of US$1.71M (from a profit a year earlier).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$43.3M |
|---|---|
| Revenue vs a year earlier | −1.5% |
| Operating profit | −US$1.05M |
| Net income | −US$1.71M |
| Period | Q2 2026 (separate) |
| Filed | 2026-07-31, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260731800847 → open original filing |
Source: DART. Information only, not investment advice.